back to top
HomeMarketMirum Prescription drugs to Host Investor Name to Share Interim Evaluation Outcomes...

Mirum Prescription drugs to Host Investor Name to Share Interim Evaluation Outcomes from the Volixibat VANTAGE and VISTAS research on June 17, 2024 By Investing.com

-

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Prescription drugs, Inc. (NASDAQ: MIRM) as we speak introduced that it’s going to host an investor name on Monday, June 17 at 8:30 a.m. ET to share interim evaluation outcomes from the Volixibat VANTAGE Part 2b examine in major biliary cholangitis (PBC) and the Volixibat VISTAS Part 2b examine in major sclerosing cholangitis (PSC).

Convention name particulars:

Monday June 17, 2024

8:30 a.m. ET / 5:30 a.m. PT

Dial-in:

U.S./Toll-Free: +1 833 470 1428

Worldwide: +1 404 975 4839

Passcode: 205511

You may additionally entry the decision by way of webcast by visiting the Occasions & Shows part on Mirum’s web site. A replay of this webcast might be accessible for 30 days.

About Mirum Prescription drugs (NASDAQ:), Inc.

Mirum Prescription drugs, Inc. is a biopharmaceutical firm devoted to remodeling the remedy of uncommon illnesses affecting kids and adults. Mirum has three authorized drugs: LIVMARLI ® (maralixibat) oral resolution, CHOLBAM ® (cholic acid) capsules, and CHENODAL ® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is authorized for the remedy of two uncommon liver illnesses affecting kids and adults. It’s authorized for the remedy of cholestatic pruritus in sufferers with Alagille syndrome within the U.S. (three months and older), in Europe (two months and older), and in different areas globally. It is usually authorized within the U.S. in cholestatic pruritus in PFIC sufferers 5 years of age and older. LIVMARLI has obtained constructive opinion by CHMP in Europe for the remedy of PFIC in sufferers three months of age and older. A call by the European Fee is anticipated by the third quarter of 2024. CHOLBAM is FDA-approved for the remedy of bile acid synthesis problems attributable to single enzyme deficiencies and adjunctive remedy of peroxisomal problems in sufferers who present indicators or signs or liver illness. CHENODAL has obtained medical necessity recognition by the FDA to deal with sufferers with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline consists of two investigational remedies for debilitating liver illnesses. Volixibat, an IBAT inhibitor, is being evaluated in two probably registrational research together with the Part 2b VISTAS examine for major sclerosing cholangitis and Part 2b VANTAGE examine for major biliary cholangitis. Lastly, CHENODAL has been evaluated in a Part 3 scientific examine, RESTORE, to deal with sufferers with CTX, with constructive topline outcomes reported in 2023.

To study extra about Mirum, go to mirumpharma.com and comply with Mirum on Fb (NASDAQ:), LinkedIn, Instagram and Twitter (X).

Traders:
Andrew McKibben
ir@mirumpharma.com

Media:
Erin Murphy
media@mirumpharma.com

Supply: Mirum Prescription drugs, Inc.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

CAPTCHA


LATEST POSTS

Down 23%! Ought to I purchase extra CrowdStrike shares for my Shares and Shares ISA?

Picture supply: Getty Photos It’s at all times a bit surreal when an organization...

Kraken begins Bitcoin (BTC) & Bitcoin Money (BCH) distribution to Mt Gox collectors

The lengthy look forward to Mt Gox collectors appears to lastly come to an finish as Kraken begins compensation The change is about to pay collectors...

GM Earnings: Basic Motors Q2 2024 revenue jumps on increased revenues | AlphaStreet

Automotive large Basic Motors Co. (NYSE: GM) Tuesday reported a pointy rise in adjusted revenue for the second quarter of 2024, reflecting a rise in...

Bitcoin rises to $66K – Who advantages from BTC’s newest surge?

Extra Bitcoin holders have remained in revenue regardless of the current decline. BTC was buying and selling above $66,000 at press time. Bitcoin’s current value actions...

Most Popular